Pharmaceuticals
Ajinomoto Bio-Pharma Services Signs Manufacturing Agreement with Humanigen for Lenzilumab, Currently in FDA-Approved Phase III Study for COVID-19
SAN DIEGO, May 27, 2020 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce it has entered into a manufacturing agreement with Humanigen, Inc., for the fill finish supply ...
2020-05-27 20:07
2336
AFT Pharmaceuticals Donates Almost $110,000 To Health Charities When They Need It Most
SYDNEY, May 26, 2020 /PRNewswire/ -- Three health charities have been given a much-needed boost at a time when the charity sector, which relies heavily on income from public events and other in-person fundraising initiatives, is being impacted by the COVID-19 pandemic. Starlight Children's Founda...
2020-05-26 08:46
2558
Nucleus Network commences Novavax' Phase 1/2 COVID-19 vaccine trial in Australia
MELBOURNE, Australia, May 26, 2020 /PRNewswire/ -- Australia's largest Phase 1 Clinical trials specialist, Nucleus Network, has today commenced dosing the first human participants for the Phase 1/2 trial of NVX‑CoV2373, a SARS-CoV-2 Recombinant Spike Protein Nanoparticle vaccine, at itsMelbourne ...
2020-05-26 08:41
2319
Innovent Announces First Patient Dosed in A Phase 1 Clinical Trial of Anti-TIGIT Monoclonal Antibody in China
SUZHOU, China, May 26, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today anno...
2020-05-26 07:30
9450
New Late-Breaking Data at EAN Indicate Evobrutinib is the First BTK Inhibitor to Report Efficacy and Safety in MS Over 108 Weeks
- Not intended for UK and U.S. based media - Investigational evobrutinib is the first and only Bruton's Tyrosine Kinase inhibitor to demonstrate high and sustained efficacy through 108 weeks in clinical studies - No new safety signals identified in the 60 week open-label extension, consistent ...
2020-05-25 08:18
2210
Nippon Express (UK) Receives WDA and GDP Certification for Company Warehouse near London Heathrow Airport
TOKYO, May 22, 2020 /PRNewswire/ -- Nippon Express (UK) Co., Ltd. (hereinafter, "NEUK"), a local subsidiary of Nippon Express Co., Ltd. based inTokyo, has been officially granted Wholesale Distribution Authorisation (WDA) and Good Distribution Practice (GDP) certification for its warehouse near L...
2020-05-22 13:00
1491
GSK partners with Samsung Biologics to secure additional manufacturing capacity for innovative biopharmaceutical portfolio
LONDON and SONGDO, South Korea, May 21, 2020 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Samsung Biologics (207940.KS) have entered into a partnership to provide GSK with additional capacity to manufacture and supply GSK's innovative biopharmaceutical therapies. Under the terms of th...
2020-05-22 07:11
6464
I-Mab and Genexine Announce China NMPA Clearance for Phase 2 Clinical Trial of TJ107/HyLeukin-7™ in Glioblastoma Multiforme
SHANGHAI, GAITHERSBURG, Md. and SEOUL, South Korea, May 21, 2020 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medi...
2020-05-21 20:00
5856
Takara Bio Selects AGC Biologics as Manufacturer of Plasmid DNA Intermediate for a Vaccine Against COVID-19 (SARS-CoV-2)
SEATTLE, May 21, 2020 /PRNewswire/ -- AGC Biologics, a global Contract Development and Manufacturing Organization (CDMO) for Biopharmaceuticals, has announced its partnership withTakara Bio.The companies will partner in the fight against COVID-19 by collaborating on a prophylaxis DNA vaccine, wit...
2020-05-21 14:00
3656
Macrogen obtained export approval for COVID-19 test kit 'AxenTM COVID-19 RT'
SEOUL, South Korea, May 21, 2020 /PRNewswire/ -- The Korean biotech company
Macrogen
2020-05-21 10:03
4156
Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology
MELBOURNE, Austrilia and SAN FRANCISCO, May 21, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has presented data on ATH434 (formerly PBT434) for the treatment of Multiple System Atrophy at the American Academy of Neurology (AAN) virtual meeting....
2020-05-21 08:58
6153
China Biologic Comments on the Xinjiang Deyuan and Shuanglin Transaction
BEIJING, May 20, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today declared that Xinjiang Deyuan Bioengineering Co., Ltd. ("Xinjiang Deyuan"), China Biolog...
2020-05-21 04:45
11511
China Biologic Reports Financial Results for the First Quarter of 2020
BEIJING, May 20, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced its unaudited financial results for the first quarter of 2020. First Quarter ...
2020-05-21 04:30
10677
Macrogen Approved for Export of its COVID-19 Test Kit
SEOUL, South Korea, May 20, 2020 /PRNewswire/ -- The Korean biotech company
Macrogen
2020-05-20 21:00
1920
Marketing Authorization Application for Luye Pharma's Rivastigmine Multi-Day Transdermal Patch Product Rivalif® under Review at EU Competent Authorities
MISBACH, Germany, May 20, 2020 /PRNewswire/ -- Luye Pharma Group announced today that the Marketing Authorization Application (MAA) within the European territory for its Rivastigmine Multi-Day Transdermal Patch (Brand Name: Rivalif® , Product Code: LY30410), an innovative drug delivery system, is ...
2020-05-20 19:34
3419
INOVIO's COVID-19 DNA Vaccine INO-4800 Demonstrates Robust Neutralizing Antibody and T Cell Immune Responses in Preclinical Models
- Publication in Nature Communications demonstrates generation of robust neutralizing antibodies and T cell responses against SARS-CoV-2 - Preliminary safety and immune responses data from Phase 1 clinical trial expected in June - Multiple animal challenge study data expected in coming weeks ...
2020-05-20 19:00
2978
I-Mab Expands Global Presence with New Hong Kong Office
SHANGHAI and ROCKVILLE, Md., May 20, 2020 /PRNewswire/ -- I-Mab (NASDAQ:IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly ...
2020-05-20 16:00
7838
Samsung Biologics Expands Business Continuity Excellence with Additional ISO22301 Certification
SONGDO, South Korea, May 19, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) announced it has attained ISO22301 certification for additional business operations, demonstrating its unsurpassed commitment to ensuring client satisfaction and operational excellence through its world-class business...
2020-05-20 07:11
1864
TauRx Reveals Study Results That Offers New Hope for Treatment of Patients With Dementia
Minimum dose of hydromethylthionine could slow clinical decline and brain atrophy in behavioural variant Fronto-Temporal Dementia as well as Alzheimer's Disease ABERDEEN, Scotland and SINGAPORE, May 19, 2020 /PRNewswire/ -- In a paper published online in theJournal of Alzheimer's Disease ( https...
2020-05-19 19:00
2311
Zai Lab Announces First Chinese Patient Dosed in the Global Phase 3 ATTACK Trial of Sulbactam- Durlobactam for Patients with Carbapenem-Resistant Acinetobacter Infections
SHANGHAI and SAN FRANCISCO, May 19, 2020 /PRNewswire/ -- Zai Lab Limited (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced dosing of the first Chinese patient in the global ATTACK (Acinetobacter Treatment Trial Against Colistin) Phase 3 registrational trial...
2020-05-19 09:45
3141
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
6217
